Trials / Active Not Recruiting
Active Not RecruitingNCT06470763
A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1)
A First-in-human, Open-label, Multicenter Phase I/II Study to Evaluate the Safety and Anti-tumor Activity of ANV600 as Single Agent and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1)
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 240 (estimated)
- Sponsor
- Anaveon AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of study ANV600-001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, immunogenicity and antitumor activity of ANV600 administered as a single agent or in combination with pembrolizumab in adult participants with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ANV600 | ANV600 administered by intravenous (IV) infusion |
| DRUG | ANV600 + pembrolizumab (KEYTRUDA®) | ANV600 administered by intravenous (IV) infusion pembrolizumab (KEYTRUDA®) administered by intravenous (IV) infusion |
Timeline
- Start date
- 2024-07-01
- Primary completion
- 2027-10-01
- Completion
- 2028-02-01
- First posted
- 2024-06-24
- Last updated
- 2026-04-14
Locations
18 sites across 7 countries: United States, Belgium, France, Germany, Netherlands, Spain, Switzerland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06470763. Inclusion in this directory is not an endorsement.